3 results about "Circulating miRNA" patented technology

The invention belongs to the technical field of biological detection, and particularly discloses a pair of echinococcosis detection markers based on serum circulating miRNA and application of the echinococcosis detection markers, the detection markers are a combination of miR-192-5p and miR-122-5p, the abundance of the miR-192-5p and the miR-122-5p in the serum of an echinococcosis patient is remarkably reduced, the miR-192-5p and the miR-122-5p are in negative correlation with echinococcosis infection, and the threshold values are 0.35 and 0.04 respectively. During detection, the relative expression level (taking caenorhabditis elegans miR-39-3p as an external reference) of caenorhabditis elegans miR-39-3p in serum is determined through qPCR, and the positive and negative properties are judged according to a threshold value; the area under the ROC curve of the marker combination reaches 0.97, and a double-blind test shows that the positive rate and the negative rate of human and mouse serum detection are 100%. The method solves the problems of missed diagnosis and misdiagnosis in existing echinococcosis detection, can be used for preparing a detection kit, realizes accurate detection, curative effect evaluation and prognosis management of echinococcosis, and has extremely high clinical application value.

The invention relates to the technical field of biomedicine, and particularly discloses a circulating miRNAs marker and application thereof. A gene next generation sequencing technology is adopted, the differential expression level of circulating miRNAs of old hypertension patients and hypertension patients accompanied with left ventricular diastolic insufficiency is analyzed, at least one of miR-19b-3p, miR-21-5p, miR-30e-5p or miR-15a-5p is screened out to serve as a biomarker, and at least one of the miR-19b-3p, the miR-21-5p, the miR-30e-5p and the miR-15a-5p is screened out to serve as the biomarker. The invention further evaluates the diagnostic efficacy of the circulating miRNAs and the combination thereof in senile hypertension accompanied by heart function impairment. As novel biomarkers, the circulating miRNAs and the combination thereof provided by the invention have the characteristics of being minimally invasive, easy to obtain, high in sensitivity, strong in specificity and the like.

The present invention describes a method for diagnosing lung cancer in a subject by detecting specific circulating miRNAs ("c-miR signature") in a biological sample obtained from that subject. Such c-miR signature provides an indication and a prognosis of lung cancer in place of or in addition to alternative known methods, including, but not limited to, low-dose computed tomography (LDCT).